These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 687511)

  • 1. Effect of high-dose melphalan on marrow and intestinal epithelium in mice pretreated with cyclophosphamide.
    Millar JL; Hudspith BN; McElwain TJ; Phelps TA
    Br J Cancer; 1978 Jul; 38(1):137-42. PubMed ID: 687511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pretreatment with cyclophosphamide on high-dose toxicity of melphalan in mice.
    Kulkarni SS; Leventon GS; Huynh L; Chow H; Dicke KA; Zander AR
    Cancer Res; 1985 Nov; 45(11 Pt 1):5431-5. PubMed ID: 3902211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclophosphamide pretreatment reduces the toxic effect of high dose melphalan on intestinal epithelium in sheep.
    Millar JL; Phelps TA; Carter RL; McElwain TJ
    Eur J Cancer (1965); 1978 Nov; 14(11):1283-5. PubMed ID: 738333
    [No Abstract]   [Full Text] [Related]  

  • 4. Acute in vivo resistance in high-dose therapy.
    Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
    Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.
    Siemann DW; Beyers KL
    Br J Cancer; 1993 Dec; 68(6):1071-9. PubMed ID: 8260357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of melphalan with prednisolone. Anti-tumor effect and normal tissue toxicity in laboratory systems.
    Selby PJ; Millar JL; Phelps TA; Gordon MY; Wilkinson R; McElwain TJ
    Cancer Chemother Pharmacol; 1981; 6(2):169-73. PubMed ID: 7307234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acceleration of bone-marrow recovery by pre-treatment with cyclophosphamide in patients receiving high-dose melphalan.
    Hedley DW; McElwain TJ; Millar JL; Gordon MY
    Lancet; 1978 Nov; 2(8097):966-8. PubMed ID: 81990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
    Ono K; Shrieve DC
    J Natl Cancer Inst; 1987 Oct; 79(4):811-5. PubMed ID: 3477662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed hematological recovery after cyclophosphamide treatment in the presence of an advanced tumor.
    DeWys WD; Mansky JM
    Cancer Res; 1973 Nov; 33(11):2662-7. PubMed ID: 4748427
    [No Abstract]   [Full Text] [Related]  

  • 10. A circadian variation of melphalan (L-phenylalanine nitrogen mustard) toxicity to murine bone marrow: relevance to cancer treatment protocols.
    Simpson HW; Stoney PJ
    Br J Haematol; 1977 Mar; 35(3):459-64. PubMed ID: 870008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The modification of melphalan toxicity in tumor bearing mice by s-2-(3-aminopropylamino)- ethylphosphorothioic acid (WR 2721).
    Millar JL; McElwain TJ; Clutterbuck RD; Wist EA
    Am J Clin Oncol; 1982 Jun; 5(3):321-8. PubMed ID: 6282111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a model of melphalan-induced gastrointestinal toxicity in mice.
    Castellino S; Elion GB; Griffith OW; Dewhirst M; Kurtzberg J; Cattley RC; Scott P; Bigner DD; Friedman HS
    Cancer Chemother Pharmacol; 1993; 31(5):376-80. PubMed ID: 8431971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in proliferation rate of human bone marrow colony-forming cells measured by a cytosine arabinoside-diffusion chamber method.
    Gordon MY; Douglas ID
    Eur J Cancer (1965); 1976 Jul; 12(7):551-5. PubMed ID: 954797
    [No Abstract]   [Full Text] [Related]  

  • 14. Factors determining cell killing by chemotherapeutic agents in vivo. II. Melphalan, chlorambucil and nitrogen mustard.
    van Putten LM; Lelieveld P
    Eur J Cancer (1965); 1971 Feb; 7(1):11-6. PubMed ID: 5576726
    [No Abstract]   [Full Text] [Related]  

  • 15. Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
    Futami H; Jansen R; MacPhee MJ; Keller J; McCormick K; Longo DL; Oppenheim JJ; Ruscetti FW; Wiltrout RH
    J Immunol; 1990 Dec; 145(12):4121-30. PubMed ID: 2258610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amino acid conferred protection against melphalan: comparison of amino acids which reduce melphalan toxicity to murine bone marrow precursor cells (CFU-C) and murine L1210 leukemia cells.
    Vistica DT; Rabon A; Rabinovitz M
    Res Commun Chem Pathol Pharmacol; 1979 Jan; 23(1):171-83. PubMed ID: 441510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide priming reduces intestinal damage in man following high dose melphalan chemotherapy.
    Selby PJ; Lopes N; Mundy J; Crofts M; Millar JL; McElwain TJ
    Br J Cancer; 1987 May; 55(5):531-3. PubMed ID: 3111515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Priming reduces the bone marrow toxicity of carboplatin.
    Gore ME; Hills CA; Siddik ZH; Sloane JP; Winkley AR; Smith IE; Millar JL
    Eur J Cancer Clin Oncol; 1987 Jan; 23(1):75-80. PubMed ID: 3297714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut protection by cyclophosphamide "priming" in patients receiving high-dose melphalan--effect of drug scheduling.
    Mansi J; Ellis E; Viner C; Mundy J; Smith T; Millar J; Milan S; Gore M; Cunningham D
    Cancer Chemother Pharmacol; 1992; 30(2):149-51. PubMed ID: 1600595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of the effect of cytotoxic drugs by radiosensitizers.
    Martin WM; McNally NJ; De Ronde J
    Br J Cancer; 1981 Jun; 43(6):756-66. PubMed ID: 7248157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.